OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $24.6667.

Several analysts recently issued reports on the stock. Truist Financial upped their price objective on shares of OrthoPediatrics from $19.00 to $20.00 and gave the company a “hold” rating in a research note on Monday, March 2nd. TD Cowen upgraded OrthoPediatrics to a “strong-buy” rating in a report on Tuesday, January 27th. BTIG Research upped their price target on OrthoPediatrics from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Wall Street Zen upgraded OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Needham & Company LLC boosted their price objective on OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, February 27th.

OrthoPediatrics Trading Up 1.3%

Shares of KIDS stock opened at $18.05 on Wednesday. OrthoPediatrics has a fifty-two week low of $15.28 and a fifty-two week high of $26.40. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.65 and a current ratio of 5.55. The stock’s fifty day moving average is $17.75 and its two-hundred day moving average is $18.10. The firm has a market capitalization of $456.30 million, a P/E ratio of -10.68 and a beta of 1.07.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. The business had revenue of $61.61 million during the quarter, compared to analyst estimates of $61.27 million. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.70%. Research analysts expect that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares during the period. Millennium Management LLC boosted its holdings in OrthoPediatrics by 55.3% in the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after purchasing an additional 106,041 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of OrthoPediatrics in the 1st quarter valued at approximately $389,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of OrthoPediatrics in the 2nd quarter valued at approximately $220,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.